Citations (103)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Irsa Shoukat & Christopher R. Mueller. (2023) Searching for DNA methylation in patients triple-negative breast cancer: a liquid biopsy approach. Expert Review of Molecular Diagnostics 23:1, pages 41-51.
Read now
Read now
Claudia Omarini, Giorgia Guaitoli, Stefania Pipitone, Luca Moscetti, Laura Cortesi, Stefano Cascinu & Federico Piacentini. (2018) Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going. Cancer Management and Research 10, pages 91-103.
Read now
Read now
Juan Jin, Wenwen Zhang, Wenfei Ji, Fang Yang & Xiaoxiang Guan. (2017) Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy. Cancer Biology & Therapy 18:6, pages 369-378.
Read now
Read now
Mohamad M. Kronfol, Mikhail G. Dozmorov, Rong Huang, Patricia W. Slattum & Joseph L. McClay. (2017) The role of epigenomics in personalized medicine. Expert Review of Precision Medicine and Drug Development 2:1, pages 33-45.
Read now
Read now
Anna Etzold, Danuta Galetzka, Eva Weis, Oliver Bartsch, Thomas Haaf, Claudia Spix, Timo Itzel, Susann Schweiger, Dennis Strand, Susanne Strand & Ulrich Zechner. (2016) CAF-like state in primary skin fibroblasts with constitutional BRCA1 epimutation sheds new light on tumor suppressor deficiency-related changes in healthy tissue. Epigenetics 11:2, pages 120-131.
Read now
Read now
Miles D Freeman, Tryphon Mazu, Jana S Miles, Selina Darling-Reed & Hernan Flores-Rozas. (2014) Inactivation of chromatin remodeling factors sensitizes cells to selective cytotoxic stress. Biologics: Targets and Therapy 8, pages 269-280.
Read now
Read now
Holger Heyn, Jesús Méndez-González & Manel Esteller. (2013) Epigenetic profiling joins personalized cancer medicine. Expert Review of Molecular Diagnostics 13:5, pages 473-479.
Read now
Read now
Articles from other publishers (96)
Zoia Rossokha, Liliia Fishchuk, Olga Lobanova, Viktoriia Vershyhora, Nataliia Medvedieva, Valeriy Cheshuk, Roman Vereshchako, Svitlana Podolska & Natalia Gorovenko. (2023) Clinical significance of determining the hypermethylation of the RUNX3 gene promoter and its cohypermethylation with the BRCA1 gene for patients with breast cancer. Journal of Cancer Research and Clinical Oncology.
Crossref
Crossref
Asad Ullah, Jaffar Khan, Abdul Qahar Khan Yasinzai, Katharine Tracy, Tena Nguyen, Bisma Tareen, Andrea Agualimpia Garcia, Saleh Heneidi & Sheila E. Segura. (2023) Metaplastic Breast Carcinoma in U.S. Population: Racial Disparities, Survival Benefit of Adjuvant Chemoradiation and Future Personalized Treatment with Genomic Landscape. Cancers 15:11, pages 2954.
Crossref
Crossref
Ashita Gadwal, Purvi Purohit, Manoj Khokhar, Jeewan Ram Vishnoi, Puneet Pareek, Ramkaran Choudhary, Poonam Elhence, Mithu Banerjee & Praveen Sharma. (2023) In silico analysis of differentially expressed-aberrantly methylated genes in breast cancer for prognostic and therapeutic targets. Clinical and Experimental Medicine 23:7, pages 3847-3866.
Crossref
Crossref
Romina Silva, Kate Glennon, Michael Metoudi, Bruce Moran, Sofia Salta, Karen Slattery, Ann Treacy, Terri Martin, Jacqui Shaw, Peter Doran, Lydia Lynch, Carmen Jeronimo, Antoinette S. Perry & Donal J. Brennan. (2023) Unveiling the epigenomic mechanisms of acquired platinum‐resistance in high‐grade serous ovarian cancer. International Journal of Cancer.
Crossref
Crossref
Robert L. Hollis. (2023) Molecular characteristics and clinical behaviour of epithelial ovarian cancers. Cancer Letters 555, pages 216057.
Crossref
Crossref
Anne-Marie Baird & Steven G. Gray. 2023. Epigenetic Cancer Therapy. Epigenetic Cancer Therapy
577
611
.
Olga Lobanova, Nataliia Medvedieva, Liliia Fishchuk, Olha Dubitska, Valeriy Cheshuk, Roman Vereshchako, Liubov Zakhartseva, Zoia Rossokha & Natalia Gorovenko. (2022) Methylation of promoter region of BRCA1 gene versus pathogenic variants of gene: risk factor or clinical marker of breast cancer. Breast Cancer Research and Treatment 196:3, pages 505-515.
Crossref
Crossref
Tira J. Tan, J. Lynn Fink, Timothy K. Tay, Binny Jaradi, Nathan Stone, Paul Waring, Kevin M. Koo, Puay Hoon Tan, Daniel S. Tan & Rebecca A. Dent. (2022)
Exquisitely Platinum-Sensitive Triple-Negative Breast Cancer, Time for
BRCA
Methylation Testing?
. JCO Precision Oncology:6.
Crossref
Crossref
Marwa Mohanad, Hend F. Yousef & Abeer A. Bahnassy. (2022) Epigenetic inactivation of DNA repair genes as promising prognostic and predictive biomarkers in urothelial bladder carcinoma patients. Molecular Genetics and Genomics 297:6, pages 1671-1687.
Crossref
Crossref
Meng Xiu, Pin Zhang, Xiang Wang, Ying Fan, Qiao Li, Qing Li, Jiayu Wang, Lin Dong, Yang Luo, Peng Yuan, Fei Ma & Binghe Xu. (2022)
Survival outcomes for dose‐dense paclitaxel plus carboplatin neoadjuvant vs standard adjuvant chemotherapy in stage
II
to
III
triple‐negative breast cancer: A prospective cohort study with propensity‐matched analysis
. International Journal of Cancer 151:4, pages 578-589.
Crossref
Crossref
Showket Hussain, Sonam Tulsyan, Sajad Ahmad Dar, Sandeep Sisodiya, Umme Abiha, Rakesh Kumar, Bhartendu Nath Mishra & Shafiul Haque. (2022) Role of epigenetics in carcinogenesis: Recent advancements in anticancer therapy. Seminars in Cancer Biology 83, pages 441-451.
Crossref
Crossref
Yan Xiao & Wencheng Gao. (2022) Therapeutic pattern and progress of neoadjuvant treatment for triple‑negative breast cancer (Review). Oncology Letters 24:1.
Crossref
Crossref
Li-yuan Feng, Bing-bing Yan, Yong-zhi Huang & Li Li. (2021) Abnormal methylation characteristics predict chemoresistance and poor prognosis in advanced high-grade serous ovarian cancer. Clinical Epigenetics 13:1.
Crossref
Crossref
Bai Xue, Shupeng Li, Xianyu Jin & Lifeng Liu. (2021) Bioinformatics analysis of mRNA and miRNA microarray to identify the key miRNA-mRNA pairs in cisplatin-resistant ovarian cancer. BMC Cancer 21:1.
Crossref
Crossref
Mohammad Aslam Khan, Kunwar Somesh Vikramdeo, Sarabjeet Kour Sudan, Seema Singh, Annelise Wilhite, Santanu Dasgupta, Rodney Paul Rocconi & Ajay Pratap Singh. (2021) Platinum-resistant ovarian cancer: From drug resistance mechanisms to liquid biopsy-based biomarkers for disease management. Seminars in Cancer Biology 77, pages 99-109.
Crossref
Crossref
Cécile Le Page, Setor Amuzu, Kurosh Rahimi, Walter Gotlieb, Jiannis Ragoussis & Patricia N. Tonin. (2021) Lessons learned from understanding chemotherapy resistance in epithelial tubo-ovarian carcinoma from BRCA1and BRCA2mutation carriers. Seminars in Cancer Biology 77, pages 110-126.
Crossref
Crossref
Ying-Cheng Chiang, Po-Han Lin & Wen-Fang Cheng. (2021) Homologous Recombination Deficiency Assays in Epithelial Ovarian Cancer: Current Status and Future Direction. Frontiers in Oncology 11.
Crossref
Crossref
Suranjana Mukherjee, Sanjukta Dasgupta, Pradyumna K. Mishra & Koel Chaudhury. (2021) Air pollution-induced epigenetic changes: disease development and a possible link with hypersensitivity pneumonitis. Environmental Science and Pollution Research 28:40, pages 55981-56002.
Crossref
Crossref
Jacob Amos Hambalek, Janay Elise Kong, Calvin Brown, Hector Enrique Munoz, Thomas Horn, Michael Bogumil, Eleni Quick, Aydogan Ozcan & Dino Di Carlo. (2021) Methylation-Sensitive Loop-Mediated Isothermal Amplification (LAMP): Nucleic Acid Methylation Detection through LAMP with Mobile Fluorescence Readout. ACS Sensors 6:9, pages 3242-3252.
Crossref
Crossref
Ksenija Nesic, Olga Kondrashova, Rachel M. Hurley, Cordelia D. McGehee, Cassandra J. Vandenberg, Gwo-Yaw Ho, Elizabeth Lieschke, Genevieve Dall, Nirashaa Bound, Kristy Shield-Artin, Marc Radke, Ashan Musafer, Zi Qing Chai, Mohammad Reza Eftekhariyan Ghamsari, Maria I. Harrell, Damien Kee, Inger Olesen, Orla McNally, Nadia Traficante, Australian Ovarian Cancer Study, Anna DeFazio, David D.L. Bowtell, Elizabeth M. Swisher, S. John Weroha, Katia Nones, Nicola Waddell, Scott H. Kaufmann, Alexander Dobrovic, Matthew J. Wakefield & Clare L. Scott. (2021)
Acquired
RAD51C
Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma
. Cancer Research 81:18, pages 4709-4722.
Crossref
Crossref
Arisa Morizono, Masahiko Tanabe, Masako Ikemura, Takeshi Sasaki, Tetsuo Ushiku & Yasuyuki Seto. (2021) Loss of BRCA1 expression and morphological features associated with BRCA1 promoter methylation status in triple-negative breast cancer. Journal of Human Genetics 66:8, pages 785-793.
Crossref
Crossref
Marina Baretti, Enusha Karunasena, Marianna Zahurak, Rosalind Walker, Yang Zhao, Thomas R. Pisanic2nd2nd, Tza‐Huei Wang, Tim F. Greten, Austin G. Duffy, Elske Gootjes, Gerrit Meijer, Henk M.W. Verheul, Nita Ahuja, James G. Herman & Nilofer S. Azad. (2021) A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype. Clinical and Translational Science 14:3, pages 954-963.
Crossref
Crossref
Oliver Trusler, Jacob Goodwin & Andrew L. Laslett. (2021) BRCA1 and BRCA2 associated breast cancer and the roles of current modelling systems in drug discovery. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1875:1, pages 188459.
Crossref
Crossref
Nirupama Sabnis, Ezek Mathew, Akpedje Dossou, Amy Zheng, Bhavani Nagarajan, Rafal Fudala & Andras G. Lacko. 2021. Overcoming Drug Resistance in Gynecologic Cancers. Overcoming Drug Resistance in Gynecologic Cancers
77
126
.
Nora Sahnane, Ileana Carnevali, Giorgio Formenti, Jvan Casarin, Sofia Facchi, Raffaella Bombelli, Eleonora Di Lauro, Domenico Memoli, Annamaria Salvati, Francesca Rizzo, Fausto Sessa & Maria Grazia Tibiletti. (2020) BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor. International Journal of Molecular Sciences 21:24, pages 9708.
Crossref
Crossref
Roshni D Kalachand, Britta Stordal, Stephen Madden, Benjamin Chandler, Julie Cunningham, Ellen L Goode, Ilary Ruscito, Elena I Braicu, Jalid Sehouli, Atanas Ignatov, Herbert Yu, Dionyssios Katsaros, Gordon B Mills, Karen H Lu, Mark S Carey, Kirsten M Timms, Jolanta Kupryjanczyk, Iwona K Rzepecka, Agnieszka Podgorska, Jessica N McAlpine, Elizabeth M Swisher, Sarah S Bernards, Ciaran O’Riain, Sharon O’Toole, John J O’Leary, David D Bowtell, David M Thomas, Katharina Prieske, Simon A Joosse, Linn Woelber, Parvesh Chaudhry, Norman Häfner, Ingo B Runnebaum & Bryan T Hennessy. (2020)
BRCA1
Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis
. JNCI: Journal of the National Cancer Institute 112:12, pages 1190-1203.
Crossref
Crossref
R.E. Miller, A. Leary, C.L. Scott, V. Serra, C.J. Lord, D. Bowtell, D.K. Chang, D.W. Garsed, J. Jonkers, J.A. Ledermann, S. Nik-Zainal, I. Ray-Coquard, S.P. Shah, X. Matias-Guiu, E.M. Swisher & L.R. Yates. (2020) ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Annals of Oncology 31:12, pages 1606-1622.
Crossref
Crossref
Rui Gou, Hui Dong & Bei Lin. (2020) Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy. Life Sciences 261, pages 118434.
Crossref
Crossref
Amal Tazzite, Hassan Jouhadi, Abdellatif Benider & Sellama Nadifi. (2020) BRCA Mutational Status is a Promising Predictive Biomarker for Platinum- based Chemotherapy in Triple-Negative Breast Cancer. Current Drug Targets 21:10, pages 962-973.
Crossref
Crossref
Allyson E. Koyen, Matthew Z. Madden, Dongkyoo Park, Elizabeth V. Minten, Priya Kapoor-Vazirani, Erica Werner, Neil T. Pfister, Ramona Haji-Seyed-Javadi, Hui Zhang, Jie Xu, Nikita Deng, Duc M. Duong, Turner J. Pecen, Zoë Frazier, Zachary D. Nagel, Jean-Bernard Lazaro, Kent W. Mouw, Nicholas T. Seyfried, Carlos S. Moreno, Taofeek K. Owonikoko, Xingming Deng & David S. Yu. (2020) EZH2 has a non-catalytic and PRC2-independent role in stabilizing DDB2 to promote nucleotide excision repair. Oncogene 39:25, pages 4798-4813.
Crossref
Crossref
William Jacot, Evelyne Lopez-Crapez, Caroline Mollevi, Florence Boissière-Michot, Joelle Simony-Lafontaine, Alexandre Ho-Pun-Cheung, Elodie Chartron, Charles Theillet, Antoinette Lemoine, Raphael Saffroy, Pierre-Jean Lamy & Séverine Guiu. (2020) BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer. Cancers 12:4, pages 828.
Crossref
Crossref
Sally Stras, Alaina Howe, Aprameya Prasad, Dominick Salerno, Omkar Bhatavdekar & Stavroula Sofou. (2019) Growth of Metastatic Triple-Negative Breast Cancer Is Inhibited by Deep Tumor-Penetrating and Slow Tumor-Clearing Chemotherapy: The Case of Tumor-Adhering Liposomes with Interstitial Drug Release. Molecular Pharmaceutics 17:1, pages 118-131.
Crossref
Crossref
Annalisa Roberti, Adolfo F. Valdes, Ramón Torrecillas, Mario F. Fraga & Agustin F. Fernandez. (2019) Epigenetics in cancer therapy and nanomedicine. Clinical Epigenetics 11:1.
Crossref
Crossref
Jorge Gómez-Miragaya, Sebastián Morán, Maria Eréndira Calleja-Cervantes, Alejandro Collado-Sole, Laia Paré, Antonio Gómez, Violeta Serra, Lacey E. Dobrolecki, Michael T. Lewis, Angel Diaz-Lagares, Pilar Eroles, Aleix Prat, Manel Esteller & Eva González-Suárez. (2019) The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models. Molecular Cancer Research 17:10, pages 2063-2076.
Crossref
Crossref
N. Tray, J. Taff & S. Adams. (2019) Therapeutic landscape of metaplastic breast cancer. Cancer Treatment Reviews 79, pages 101888.
Crossref
Crossref
Tidarat Nhukeaw, Khwanjira Hongthong, Paul J. Dyson & Adisorn Ratanaphan. (2019) Cellular responses of BRCA1-defective HCC1937 breast cancer cells induced by the antimetastasis ruthenium(II) arene compound RAPTA-T. Apoptosis 24:7-8, pages 612-622.
Crossref
Crossref
Yen Ting Shen, Lucy Wang, James C. Evans, Christine Allen & Micheline Piquette-Miller. (2019) Development of a Bioluminescent BRCA1-Deficient Xenograft Model of Disseminated, High-Grade Serous Ovarian Cancer. International Journal of Molecular Sciences 20:10, pages 2498.
Crossref
Crossref
Shilpy Sharma. 2019. Prognostic Epigenetics. Prognostic Epigenetics
397
409
.
Mohamad M. Kronfol & Joseph L. McClay. 2019. Prognostic Epigenetics. Prognostic Epigenetics
375
395
.
Aleksandra Majchrzak-Celińska & Wanda Baer-Dubowska. 2019. Pharmacoepigenetics. Pharmacoepigenetics
101
112
.
Jolein Mijnes, Jürgen Veeck, Nadine T. Gaisa, Eduard Burghardt, Tim C. de Ruijter, Sonja Gostek, Edgar Dahl, David Pfister, Sebastian C. Schmid, Ruth Knüchel & Michael Rose. (2018) Promoter methylation of DNA damage repair (DDR) genes in human tumor entities: RBBP8/CtIP is almost exclusively methylated in bladder cancer. Clinical Epigenetics 10:1.
Crossref
Crossref
Yanina Natanzon, Ellen L. Goode & Julie M. Cunningham. (2018) Epigenetics in ovarian cancer. Seminars in Cancer Biology 51, pages 160-169.
Crossref
Crossref
D.Gareth R. Evans, Elke M. van Veen, Helen J. Byers, Andrew J. Wallace, Jamie M. Ellingford, Glenda Beaman, Javier Santoyo-Lopez, Timothy J. Aitman, Diana M. Eccles, Fiona I. Lalloo, Miriam J. Smith & William G. Newman. (2018) A Dominantly Inherited 5′ UTR Variant Causing Methylation-Associated Silencing of BRCA1 as a Cause of Breast and Ovarian Cancer. The American Journal of Human Genetics 103:2, pages 213-220.
Crossref
Crossref
Angela Nebbioso, Francesco Paolo Tambaro, Carmela Dell’Aversana & Lucia Altucci. (2018) Cancer epigenetics: Moving forward. PLOS Genetics 14:6, pages e1007362.
Crossref
Crossref
Melina-Theoni Gyparaki & Athanasios G. Papavassiliou. (2018) Epigenetic Pathways Offer Targets for Ovarian Cancer Treatment. Clinical Breast Cancer 18:3, pages 189-191.
Crossref
Crossref
Leyla Norouzi-Barough, Mohammad Reza Sarookhani, Mohammadreza Sharifi, Sahar Moghbelinejad, Saranaz Jangjoo & Rasoul Salehi. (2018) Molecular mechanisms of drug resistance in ovarian cancer. Journal of Cellular Physiology 233:6, pages 4546-4562.
Crossref
Crossref
Daniel H. Ahn, Josh Reardon, Chul W. Ahn, Manojkumar Bupathi, Sameh Mikhail, Christina Sing‐Ying Wu & Tanios Bekaii‐Saab. (2017) Biweekly cisplatin and gemcitabine in patients with advanced biliary tract cancer. International Journal of Cancer 142:8, pages 1671-1675.
Crossref
Crossref
Sarah S. Bernards, Kathryn P. Pennington, Maria I. Harrell, Kathy J. Agnew, Rochelle L. Garcia, Barbara M. Norquist & Elizabeth M. Swisher. (2018) Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma. Gynecologic Oncology 148:2, pages 281-285.
Crossref
Crossref
Daiana Cosmina Temian, Laura Ancuta PopAlexandra Iulia IrimieIoana Berindan-Neagoe. (2018) The Epigenetics of Triple-Negative and Basal-Like Breast Cancer: Current Knowledge. Journal of Breast Cancer 21:3, pages 233.
Crossref
Crossref
Azad Kumar, Devashree Jahagirdar, Shruti Purohit & Nilesh Kumar Sharma. 2018. Emerging Developments and Practices in Oncology. Emerging Developments and Practices in Oncology
28
55
.
Jonathan B. Dayton & Stephen R. Piccolo. (2017) Classifying cancer genome aberrations by their mutually exclusive effects on transcription. BMC Medical Genomics 10:S4.
Crossref
Crossref
Tushar Tomar, Nicolette G. Alkema, Leroy Schreuder, Gert Jan Meersma, Tim de Meyer, Wim van Criekinge, Harry G. Klip, Heidi Fiegl, Els van Nieuwenhuysen, Ignace Vergote, Martin Widschwendter, Ed Schuuring, Ate G. J. van der Zee, Steven de Jong & G. Bea A. Wisman. (2017) Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer. BMC Medicine 15:1.
Crossref
Crossref
Katharina Prieske, Stefan Prieske, Simon A. Joosse, Fabian Trillsch, Donata Grimm, Eike Burandt, Sven Mahner, Barbara Schmalfeldt, Karin Milde-Langosch, Leticia Oliveira-Ferrer & Linn Woelber. (2017)
Loss of
BRCA1
promotor hypermethylation in recurrent high-grade ovarian cancer
. Oncotarget 8:47, pages 83063-83074.
Crossref
Crossref
Veronica Davalos, Anna Martinez-Cardus & Manel Esteller. (2017) The Epigenomic Revolution in Breast Cancer. The American Journal of Pathology 187:10, pages 2163-2174.
Crossref
Crossref
András Füredi, Kornélia Szebényi, Szilárd Tóth, Mihály Cserepes, Lilla Hámori, Veronika Nagy, Edina Karai, Péter Vajdovich, Tímea Imre, Pál Szabó, Dávid Szüts, József Tóvári & Gergely Szakács. (2017) Pegylated liposomal formulation of doxorubicin overcomes drug resistance in a genetically engineered mouse model of breast cancer. Journal of Controlled Release 261, pages 287-296.
Crossref
Crossref
F. Perri, F. Longo, M. Giuliano, F. Sabbatino, G. Favia, F. Ionna, R. Addeo, G. Della Vittoria Scarpati, G. Di Lorenzo & S. Pisconti. (2017) Epigenetic control of gene expression: Potential implications for cancer treatment. Critical Reviews in Oncology/Hematology 111, pages 166-172.
Crossref
Crossref
Robbert D.A. Weren, Arjen R. Mensenkamp, Michiel Simons, Astrid Eijkelenboom, Aisha S. Sie, Hicham Ouchene, Monique van Asseldonk, Encarna B. Gomez-Garcia, Marinus J. Blok, Joanne A. de Hullu, Marcel R. Nelen, Alexander Hoischen, Johan Bulten, Bastiaan B.J. Tops, Nicoline Hoogerbrugge & Marjolijn J.L. Ligtenberg. (2017)
Novel
BRCA1
and
BRCA2
Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas
. Human Mutation 38:2, pages 226-235.
Crossref
Crossref
Margarita Romeo, Niki Karachaliou, Imane Chaid, Cristina Queralt, Itziar De Aguirre, María del Carmen Gómez, María Sanchez-Ronco, Joaquim Radua, José Luís Ramírez & Rafael Rosell. (2017) Low RAP80 mRNA Expression Correlates with Shorter Survival in Sporadic High-Grade Serous Ovarian Carcinoma. The International Journal of Biological Markers 32:1, pages 90-95.
Crossref
Crossref
Aglaya G. Iyevleva & Evgeny N. Imyanitov. (2016) Cytotoxic and targeted therapy for hereditary cancers. Hereditary Cancer in Clinical Practice 14:1.
Crossref
Crossref
Dan Gao, James G. Herman & Mingzhou Guo. (2016) The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer. Oncotarget 7:24, pages 37331-37346.
Crossref
Crossref
Wei Xuan, Hailin Zhao, James Hankin, Lin Chen, Shanglong Yao & Daqing Ma. (2016) Local anesthetic bupivacaine induced ovarian and prostate cancer apoptotic cell death and underlying mechanisms in vitro. Scientific Reports 6:1.
Crossref
Crossref
Francesca MenghiKoichiro InakiXingYi WooPooja A. KumarKrzysztof R. GrzedaAnkit MalhotraVinod YadavHyunsoo KimEladio J. MarquezDuygu UcarPhung T. ShreckengastJoel P. WagnerGeorge MacIntyreKrishna R. Murthy KaruturiRalph ScullyJames Keck, Jeffrey H. ChuangEdison T. Liu. (2016) The tandem duplicator phenotype as a distinct genomic configuration in cancer. Proceedings of the National Academy of Sciences 113:17.
Crossref
Crossref
Vanesa Nogales, William C. Reinhold, Sudhir Varma, Anna Martinez-Cardus, Catia Moutinho, Sebastian Moran, Holger Heyn, Ana Sebio, Agusti Barnadas, Yves Pommier & Manel Esteller. (2015) Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs. Oncotarget 7:3, pages 3084-3097.
Crossref
Crossref
M. Bitzer & N.P. Malek. 2016. Medical Epigenetics. Medical Epigenetics
843
858
.
Ang Sun. 2016. Gynecological Cancers. Gynecological Cancers
23
47
.
Sabita N. Saldanha & Shivani Soni. 2016. Epigenetic Advancements in Cancer. Epigenetic Advancements in Cancer
1
26
.
Alexander Dobrovic. 2016. Molecular Pathology in Cancer Research. Molecular Pathology in Cancer Research
261
277
.
Clémence Basse & Michel Arock. (2014) The increasing roles of epigenetics in breast cancer: Implications for pathogenicity, biomarkers, prevention and treatment. International Journal of Cancer 137:12, pages 2785-2794.
Crossref
Crossref
Li Zhang & Xinghua Long. (2015) Association of BRCA1 promoter methylation with sporadic breast cancers: Evidence from 40 studies. Scientific Reports 5:1.
Crossref
Crossref
Melina-Theoni Gyparaki & Athanasios G. Papavassiliou. (2015) WITHDRAWN: Epigenetic Pathways Offer Targets for Ovarian Cancer Treatment. Clinical Ovarian and Other Gynecologic Cancer.
Crossref
Crossref
Kishan AT Naipal & Dik C van Gent. (2015) PARP inhibitors: the journey from research hypothesis to clinical approval. Personalized Medicine 12:2, pages 139-154.
Crossref
Crossref
Clare Stirzaker, Elena Zotenko, Jenny Z. Song, Wenjia Qu, Shalima S. Nair, Warwick J. Locke, Andrew Stone, Nicola J. Armstong, Mark D. Robinson, Alexander Dobrovic, Kelly A. Avery-Kiejda, Kate M. Peters, Juliet D. French, Sandra Stein, Darren J. Korbie, Matt Trau, John F. Forbes, Rodney J. Scott, Melissa A. Brown, Glenn D. Francis & Susan J. Clark. (2015) Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value. Nature Communications 6:1.
Crossref
Crossref
Yang Fan, Long Wang, Xuechuan Han, Xueqin Liu, Hongyun Ma & Yonghui Ding. (2015) Upregulation of Fas in epithelial ovarian cancer reverses the development of resistance to Cisplatin. BMB Reports 48:1, pages 30-35.
Crossref
Crossref
Holger Heyn. 2015. Epigenetic Cancer Therapy. Epigenetic Cancer Therapy
677
698
.
Steven G. Gray. 2015. Epigenetic Cancer Therapy. Epigenetic Cancer Therapy
613
637
.
Alexandre F. Aissa & Lusânia M.G. Antunes. 2015. Personalized Epigenetics. Personalized Epigenetics
245
282
.
Fabio Coppedè, Angela Lopomo & Lucia Migliore. 2015. Personalized Epigenetics. Personalized Epigenetics
183
220
.
Jesus Mendez-Gonzalez & Juan Sandoval. 2015. Computational and Statistical Epigenomics. Computational and Statistical Epigenomics
187
217
.
Shaojun Zhang, Yuan Yuan & Dapeng Hao. (2014) A Genomic Instability Score in Discriminating Nonequivalent Outcomes of BRCA1/2 Mutations and in Predicting Outcomes of Ovarian Cancer Treated with Platinum-Based Chemotherapy. PLoS ONE 9:12, pages e113169.
Crossref
Crossref
Satish Gupta, Katarzyna Jaworska-Bieniek, Steven A. Narod, Jan Lubinski, Tomasz K. Wojdacz & Anna Jakubowska. (2014) Methylation of the BRCA1 promoter in peripheral blood DNA is associated with triple-negative and medullary breast cancer. Breast Cancer Research and Treatment 148:3, pages 615-622.
Crossref
Crossref
Jianping Lu, Di Wu, Chuanxing Li, Meng Zhou & Dapeng Hao. (2014) Correlation between gene expression and mutator phenotype predicts homologous recombination deficiency and outcome in ovarian cancer. Journal of Molecular Medicine 92:11, pages 1159-1168.
Crossref
Crossref
T. Ignatov, H. Eggemann, S. D. Costa, A. Roessner, T. Kalinski & A. Ignatov. (2014) BRCA1 promoter methylation is a marker of better response to platinum–taxane-based therapy in sporadic epithelial ovarian cancer. Journal of Cancer Research and Clinical Oncology 140:9, pages 1457-1463.
Crossref
Crossref
Maxim Ivanov, Isabel Barragan & Magnus Ingelman-Sundberg. (2014) Epigenetic mechanisms of importance for drug treatment. Trends in Pharmacological Sciences 35:8, pages 384-396.
Crossref
Crossref
Kyungsoo Ha, Warren Fiskus, Dong Soon Choi, Srividya Bhaskara, Leandro Cerchietti, Santhana G. T. Devaraj, Bhavin Shah, Sunil Sharma, Jenny C. Chang, Ari M. Melnick, Scott Hiebert & Kapil N. Bhalla. (2014) Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells. Oncotarget 5:14, pages 5637-5650.
Crossref
Crossref
Mou-Ze Liu, Howard L McLeod, Fa-Zhong He, Xiao-Ping Chen, Hong-Hao Zhou, Yan Shu & Wei Zhang. (2014) Epigenetic perspectives on cancer chemotherapy response. Pharmacogenomics 15:5, pages 699-715.
Crossref
Crossref
Mathilde Foedermayr, Miriam Sebesta, Margaretha Rudas, Anna S. Berghoff, Regina Promberger, Matthias Preusser, Peter Dubsky, Florian Fitzal, Michael Gnant, Guenther G. Steger, Ansgar Weltermann, Christoph C. Zielinski, Otto Zach & Rupert Bartsch. (2014) BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy. Cancer Chemotherapy and Pharmacology 73:4, pages 771-778.
Crossref
Crossref
Brigitte L. Thériault, Halesha D. Basavarajappa, Harvey Lim, Sanja Pajovic, Brenda L. Gallie & Timothy W. Corson. (2014) Transcriptional and Epigenetic Regulation of KIF14 Overexpression in Ovarian Cancer. PLoS ONE 9:3, pages e91540.
Crossref
Crossref
Joris R Julsing & Godefridus J Peters. (2014) Methylation of DNA repair genes and the efficacy of DNA targeted anticancer treatment. Oncology Discovery 2:1, pages 3.
Crossref
Crossref
Priyanka Sharma, Shane R Stecklein, Bruce F Kimler, Geetika Sethi, Brian K Petroff, Teresa A Phillips, Ossama W Tawfik, Andrew K Godwin & Roy A Jensen. (2014) The prognostic value of BRCA1 promoter methylation in early stage triple negative breast cancer. journal of Cancer Therapeutics and Research 3:1, pages 2.
Crossref
Crossref
Jun Nakamura. (2014) Methylation-mediated gene silencing as biomarkers of gastric cancer: A review. World Journal of Gastroenterology 20:34, pages 11991.
Crossref
Crossref
Catia Moutinho, Anna Martinez-Cardús, Cristina Santos, Valentin Navarro-Pérez, Eva Martínez-Balibrea, Eva Musulen, F. Javier Carmona, Andrea Sartore-Bianchi, Andrea Cassingena, Salvatore Siena, Elena Elez, Josep Tabernero, Ramon Salazar, Albert Abad & Manel Esteller. (2014) Epigenetic Inactivation of the BRCA1 Interactor SRBC and Resistance to Oxaliplatin in Colorectal Cancer. JNCI: Journal of the National Cancer Institute 106:1.
Crossref
Crossref
Gayathri R. Devi, Jennifer L. Allensworth, Myron K. Evans & Scott J. Sauer. 2014. Cancer. Cancer
3
14
.
Liang Wu, Fengliang Wang, Ruobing Xu, Simin Zhang, Xianzhen Peng, Yan Feng, Jianming Wang & Cheng Lu. (2013) Promoter methylation of BRCA1 in the prognosis of breast cancer: a meta-analysis. Breast Cancer Research and Treatment 142:3, pages 619-627.
Crossref
Crossref
Olafur A. Stefansson & Manel Esteller. (2013) Epigenetic Modifications in Breast Cancer and Their Role in Personalized Medicine. The American Journal of Pathology 183:4, pages 1052-1063.
Crossref
Crossref
Pierre-Alexandre Vidi, James F. Leary & Sophie A. Lelièvre. (2013) Building risk-on-a-chip models to improve breast cancer risk assessment and prevention. Integrative Biology 5:9, pages 1110-1118.
Crossref
Crossref
Dominic Varga, Miriam Deniz, Lukas Schwentner & Lisa Wiesmüller. (2013) Ovarian Cancer: In Search of Better Marker Systems Based on DNA Repair Defects. International Journal of Molecular Sciences 14:1, pages 640-673.
Crossref
Crossref